SCHEDULE 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SCHEDULE 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SCHEDULE 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

POS AM - Tectonic Therapeutic, Inc. (0001681087) (Filer)

S-1 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

10-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight

TD Cowen initiated coverage of Tectonic Therapeutic with a rating of Buy

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction ("HFrEF") in March 2025Cash and cash equivalents of $141.2 million as of December 31, 2024 and February 2025 private placement gross proceeds of approximately $185.0 million, together expected to provide

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025. TD Cowen 45th Annual Health Care Conference Date:March 5, 2025Time:9:50 AM ESTLocation:Boston, MAFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link  Leerink Partners Global Healthcare ConferenceDate: March 11, 2025Time:11:20 A

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $185.0 million. Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.00 per share to fund investors and $54.14 per share to individual investors that are either an officer or director of Tectonic. The PIPE financing included participation from new and existing invest

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, click here. Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York on December 3-5, 2024. Piper Sandler 36th Annual Healthcare Conference details:  Meetings:Presentation and one-on-one meetingsPresentation Date:Tuesday, December 3rd, 2024Presentation Time:12:30 PM ETPresenter:Alise Reicin, MD, President

Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow ("RPF")TX45 showed a favorable safety profile, with no observed injection site reactions, immunogenicity, or detection of anti-drug antibodiesRPF-based exposure-response model enabled APEX Phase 2 dose selectionUpcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodynamic, proof-of-concept trial data expected in late 1Q or early 2Q'2025, and APEX Phase 2 clinical trial data expected in 2026 WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeut

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that it will present a poster at AHA 2024 highlighting Phase 1a data for its lead asset TX000045 ("TX45"), a long-acting, relaxin. TX45 is being developed as a potential best-in-class therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF"). Tectonic announced topline results from the study on September 19, 2024. AHA 2024 P

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024 Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tolerability profile observed at lower doses, with topline trial results expected in the second quarter of 2025 WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)